Director sold ~$640K of Regeneron Pharmaceuticals
Scheduled in advanceLoading…
Reporting person on SEC Form 4
Huda Y Zoghbi
Director
Disclosures on record
18
Companies involved
1
Disclosure history
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Director sold ~$258K of Regeneron Pharmaceuticals
Scheduled in advanceDirector sold ~$233K of Regeneron Pharmaceuticals
Scheduled in advanceDirector sold ~$172K of Regeneron Pharmaceuticals
Scheduled in advanceDirector sold ~$163K of Regeneron Pharmaceuticals
Scheduled in advanceDirector sold ~$162K of Regeneron Pharmaceuticals
Scheduled in advanceDirector sold ~$126K of Regeneron Pharmaceuticals
Scheduled in advanceDirector sold ~$44K of Regeneron Pharmaceuticals
Scheduled in advanceDirector sold ~$41K of Regeneron Pharmaceuticals
Scheduled in advanceDirector sold ~$39K of Regeneron Pharmaceuticals
Scheduled in advanceDirector sold ~$38K of Regeneron Pharmaceuticals
Scheduled in advanceDirector sold ~$3.2K of Regeneron Pharmaceuticals
Scheduled in advanceDerivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.